Literature DB >> 23548164

Neoclerodanes as atypical opioid receptor ligands.

Thomas E Prisinzano1.   

Abstract

The neoclerodane diterpene salvinorin A is the major active component of the hallucinogenic mint plant Salvia divinorum Epling and Játiva (Lamiaceae). Since the finding that salvinorin A exerts its potent psychotropic actions through the activation of opioid receptors, the site of action of morphine and related analogues, there has been much interest in elucidating the underlying mechanisms behind its effects. These effects are particularly remarkable because (1) salvinorin A is the first reported non-nitrogenous opioid receptor agonist and (2) its effects are not mediated through the previously investigated targets of psychotomimetics. This Perspective outlines our research program, illustrating a new direction to the development of tools to further elucidate the biological mechanisms of drug tolerance and dependence. The information gained from these efforts is expected to facilitate the design of novel agents to treat pain, drug abuse, and other central nervous system disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23548164      PMCID: PMC3671615          DOI: 10.1021/jm400388u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  80 in total

Review 1.  Biotransformation reactions of five-membered aromatic heterocyclic rings.

Authors:  Deepak K Dalvie; Amit S Kalgutkar; S Cyrus Khojasteh-Bakht; R Scott Obach; John P O'Donnell
Journal:  Chem Res Toxicol       Date:  2002-03       Impact factor: 3.739

2.  Autoxidation of salvinorin A under basic conditions.

Authors:  Thomas A Munro; Glenn W Goetchius; Bryan L Roth; Timothy A Vortherms; Mark A Rizzacasa
Journal:  J Org Chem       Date:  2005-11-25       Impact factor: 4.354

Review 3.  Preclinical pharmacology and opioid combinations.

Authors:  Gavril W Pasternak
Journal:  Pain Med       Date:  2012-03       Impact factor: 3.750

4.  Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum.

Authors:  L J Valdés; H M Chang; D C Visger; M Koreeda
Journal:  Org Lett       Date:  2001-11-29       Impact factor: 6.005

Review 5.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

6.  A facile method for the preparation of deuterium labeled salvinorin A: synthesis of [2,2,2-2H3]-salvinorin A.

Authors:  Kevin Tidgewell; Wayne W Harding; Mark Schmidt; Kenneth G Holden; Daryl J Murry; Thomas E Prisinzano
Journal:  Bioorg Med Chem Lett       Date:  2004-10-18       Impact factor: 2.823

7.  Hepatotoxicity of germander (Teucrium chamaedrys L.) and one of its constituent neoclerodane diterpenes teucrin A in the mouse.

Authors:  S A Kouzi; R J McMurtry; S D Nelson
Journal:  Chem Res Toxicol       Date:  1994 Nov-Dec       Impact factor: 3.739

8.  Salvinorins D-F, new neoclerodane diterpenoids from Salvia divinorum, and an improved method for the isolation of salvinorin A.

Authors:  Thomas A Munro; Mark A Rizzacasa
Journal:  J Nat Prod       Date:  2003-05       Impact factor: 4.050

9.  Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain.

Authors:  Lars Arendt-Nielsen; Anne E Olesen; Camilla Staahl; Frédérique Menzaghi; Sherron Kell; Gilbert Y Wong; Asbjørn M Drewes
Journal:  Anesthesiology       Date:  2009-09       Impact factor: 7.892

Review 10.  Under-treatment of cancer pain.

Authors:  Alysa Fairchild
Journal:  Curr Opin Support Palliat Care       Date:  2010-03       Impact factor: 2.302

View more
  7 in total

1.  Semisynthesis and Kappa-Opioid Receptor Activity of Derivatives of Columbin, a Furanolactone Diterpene.

Authors:  Anil Yilmaz; Rachel Saylor Crowley; Alexander M Sherwood; Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2017-07-18       Impact factor: 4.050

2.  In Vitro, In Vivo and In Silico Characterization of a Novel Kappa-Opioid Receptor Antagonist.

Authors:  Kristina Puls; Aina-Leonor Olivé-Marti; Szymon Pach; Birgit Pinter; Filippo Erli; Gerhard Wolber; Mariana Spetea
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-28

3.  A selective delta opioid receptor antagonist based on a stilbene core.

Authors:  Alyssa M Hartung; Hernan A Navarro; David F Wiemer; Jeffrey D Neighbors
Journal:  Bioorg Med Chem Lett       Date:  2015-10-23       Impact factor: 2.823

4.  Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.

Authors:  Prabhakar R Polepally; Krzysztof Huben; Eyal Vardy; Vincent Setola; Philip D Mosier; Bryan L Roth; Jordan K Zjawiony
Journal:  Eur J Med Chem       Date:  2014-08-23       Impact factor: 6.514

5.  Stilbenes as κ-selective, non-nitrogenous opioid receptor antagonists.

Authors:  Alyssa M Hartung; John A Beutler; Hernán A Navarro; David F Wiemer; Jeffrey D Neighbors
Journal:  J Nat Prod       Date:  2014-01-23       Impact factor: 4.050

6.  Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.

Authors:  Andrew P Riley; Chad E Groer; David Young; Amy W Ewald; Bronwyn M Kivell; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2014-12-09       Impact factor: 7.446

Review 7.  Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders.

Authors:  Eduardo R Butelman; Mary Jeanne Kreek
Journal:  Front Pharmacol       Date:  2015-09-08       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.